Testosterone for the aging male; current evidence and recommended practice

Roger D Stanworth, T Hugh JonesCentre of Diabetes and Endocrinology, Barnsley Hospital NHS Foundation Trust, Barnsley, South Yorkshire, United Kingdom; Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, South Yorkshire, United KingdomAbstract: An internation...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Roger D Stanworth, T Hugh Jones
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/b4706b0e8efb4b05b36ed3793940fbcb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b4706b0e8efb4b05b36ed3793940fbcb
record_format	dspace
spelling	oai:doaj.org-article:b4706b0e8efb4b05b36ed3793940fbcb2021-12-02T00:36:40ZTestosterone for the aging male; current evidence and recommended practice1178-1998https://doaj.org/article/b4706b0e8efb4b05b36ed3793940fbcb2008-03-01T00:00:00Zhttps://www.dovepress.com/testosterone-for-the-aging-male-current-evidence-and-recommended-pract-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Roger D Stanworth, T Hugh JonesCentre of Diabetes and Endocrinology, Barnsley Hospital NHS Foundation Trust, Barnsley, South Yorkshire, United Kingdom; Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, South Yorkshire, United KingdomAbstract: An international consensus document was recently published and provides guidance on the diagnosis, treatment and monitoring of late-onset hypogonadism (LOH) in men. The diagnosis of LOH requires biochemical and clinical components. Controversy in defining the clinical syndrome continues due to the high prevalence of hypogonadal symptoms in the aging male population and the non-specific nature of these symptoms. Further controversy surrounds setting a lower limit of normal testosterone, the limitations of the commonly available total testosterone result in assessing some patients and the unavailability of reliable measures of bioavailable or free testosterone for general clinical use. As with any clinical intervention testosterone treatment should be judged on a balance of risk versus benefit. The traditional benefits of testosterone on sexual function, mood, strength and quality of life remain the primary goals of treatment but possible beneficial effects on other parameters such as bone density, obesity, insulin resistance and angina are emerging and will be reviewed. Potential concerns regarding the effects of testosterone on prostate disease, aggression and polycythaemia will also be addressed. The options available for treatment have increased in recent years with the availability of a number of testosterone preparations which can reliably produce physiological serum concentrations.Keywords: review, testosterone, male, agingRoger D StanworthT Hugh JonesDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 3, Pp 25-44 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Roger D Stanworth T Hugh Jones Testosterone for the aging male; current evidence and recommended practice
description	Roger D Stanworth, T Hugh JonesCentre of Diabetes and Endocrinology, Barnsley Hospital NHS Foundation Trust, Barnsley, South Yorkshire, United Kingdom; Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, South Yorkshire, United KingdomAbstract: An international consensus document was recently published and provides guidance on the diagnosis, treatment and monitoring of late-onset hypogonadism (LOH) in men. The diagnosis of LOH requires biochemical and clinical components. Controversy in defining the clinical syndrome continues due to the high prevalence of hypogonadal symptoms in the aging male population and the non-specific nature of these symptoms. Further controversy surrounds setting a lower limit of normal testosterone, the limitations of the commonly available total testosterone result in assessing some patients and the unavailability of reliable measures of bioavailable or free testosterone for general clinical use. As with any clinical intervention testosterone treatment should be judged on a balance of risk versus benefit. The traditional benefits of testosterone on sexual function, mood, strength and quality of life remain the primary goals of treatment but possible beneficial effects on other parameters such as bone density, obesity, insulin resistance and angina are emerging and will be reviewed. Potential concerns regarding the effects of testosterone on prostate disease, aggression and polycythaemia will also be addressed. The options available for treatment have increased in recent years with the availability of a number of testosterone preparations which can reliably produce physiological serum concentrations.Keywords: review, testosterone, male, aging
format	article
author	Roger D Stanworth T Hugh Jones
author_facet	Roger D Stanworth T Hugh Jones
author_sort	Roger D Stanworth
title	Testosterone for the aging male; current evidence and recommended practice
title_short	Testosterone for the aging male; current evidence and recommended practice
title_full	Testosterone for the aging male; current evidence and recommended practice
title_fullStr	Testosterone for the aging male; current evidence and recommended practice
title_full_unstemmed	Testosterone for the aging male; current evidence and recommended practice
title_sort	testosterone for the aging male; current evidence and recommended practice
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/b4706b0e8efb4b05b36ed3793940fbcb
work_keys_str_mv	AT rogerdstanworth testosteronefortheagingmalecurrentevidenceandrecommendedpractice AT thughjones testosteronefortheagingmalecurrentevidenceandrecommendedpractice
_version_	1718403641525665792

Testosterone for the aging male; current evidence and recommended practice

Ejemplares similares